VivoSeq
Other

Lozenge

0

Pipeline Programs↗

0

Active Trials↗

5

Companies Involved↗

Lozenge is an early-stage landscape with 0 programs across 5 companies. The most active players are GSK, Boehringer Ingelheim, Fertin Pharma A/S.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

95/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalF

Fertin Pharma A/S

0 programs

PreclinicalP

Pharmaceutical Productions Inc.

0 programs

PreclinicalN

Next Gen Pharma India Pvt. Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

19

clinical trials

Completed18 · 95%
Withdrawn1 · 5%

Clinical Trials

Trial Activity

19 trials

Study to Evaluate Safety, Tolerability and Pharmacokinetics of Increasing Repeated Oral Doses of Ambroxol Lozenges in Healthy Male Volunteers
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT02194283·34 enrolled
Pilot Pharmacokinetic Study of Investigational Sublingual Nicotine Tablet Versus COMMIT Nicotine Lozenge
Completed·PPharmaceutical Productions Inc.·Phase 1·NCT01887847·6 enrolled
Pilot Pharmacokinetic Study of New Nicotine Lozenge Formulations
Completed·PPierre Fabre Medicament·Phase 1·NCT01574898·13 enrolled
Effect of Lozenges Containing Probiotic Lactobacilli on Enamel Demineralization Assed by QLF
Completed·UUniversity of Copenhagen·N/A·NCT01738958·66 enrolled
Oral Mucosal Effects In Adult Smokers Associated With Two Nicotine Lozenge Formulations
Completed·NNiconovum USA·Phase 1·NCT03087786·100 enrolled
To Assess the Bioequivalence of the 4mg Prototype Mini Nicotine Lozenge to the Reference Product (Nicorette) in Healthy Smokers
Completed·GSK logoGSK·Phase 1·NCT03543137·37 enrolled
Early Effects of a New Oral Nicotine Replacement Product and NiQuitin™ Lozenge
Completed·MMcNeil AB·Phase 2·NCT01075659·200 enrolled
Comparing NicoBloc to Nicotine Lozenges
Completed·UUniversity of Alabama at Birmingham·Phase 2/3·NCT03720899·45 enrolled
Bioequivalence of Flurbiprofen Lozenge vs Strepfen
Completed·AAziende Chimiche Riunite Angelini Francesco S.p.A·Phase 1·NCT04670601·24 enrolled
Probiotic Lozenge Reduce Streptococcus Mutans in Plaque in Orthodontic Bracket Patients
Completed·NNext Gen Pharma India Pvt. Ltd.·Phase 3·NCT02357771·30 enrolled
Pharmacokinetic Study of 4 mg Nicotine Lozenge.
Completed·GSK logoGSK·Phase 2·NCT01669122·40 enrolled
Single-Dose Bioequivalence Study Comparing Two 4 mg Nicotine Lozenges
Completed·FFertin Pharma A/S·Phase 1·NCT03432312·42 enrolled
Single-Dose Bioequivalence Study Comparing Two 2 mg Nicotine Lozenges
Completed·FFertin Pharma A/S·Phase 1·NCT03432273·42 enrolled
Palatability Study of Five Formulations of Benzydamine HCl Lozenges
Completed·AAziende Chimiche Riunite Angelini Francesco S.p.A·Phase 1·NCT07199543·120 enrolled
Relative Bioavailability of Ambroxol Hydrochloride Lozenge in Comparison to Ambroxol Hydrochloride Syrup (Mucosolvan®) in Healthy Female and Male Volunteers
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT02194296·20 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)